convective mixing efficiency is reduced as a result of the rapid nuclear burning. Because hydrogen burning then occurs closer to the surface, stellar evolution is accelerated, in agreement with observations (13, 14) . The model results can explain the gross properties and the observed variations in the chemical composition of Sakurai's Object, including the production of lithium and the low carbon isotopic ratio ( 12 C/ 13 C ≈ 4). Hajduk et al. even argue that born-again giants may be the dominant source of 13 C in the Universe. Indeed, certain presolar grains in primitive meteorites found on Earth may come from born-again giants (15) .
Given the unprecedented pace with which Sakurai's Object has evolved over the past decade, its future behavior will be scrutinized closely. As the star heats up, it will eventually destroy its obscuring cocoon of dust and become visible again inside the new planetary nebula. Studies of its chemical composition would then be high on the agenda. The real-time evolution of Sakurai's Object is likely to continue to unfold in the coming decades, to the delight of astronomers.
M
icrotubules are the principal cytoskeletal components of axons, the long processes that link the excitable cells (neurons) of the nervous system. Thus, control of microtubule polymerization and stability is a key regulatory step in axon growth during development and regeneration after nerve injury. Moreover, the regulation of these two processes is an important target of both growth-promoting and growth-inhibiting extracellular signals.
Microtubules are linear structures composed of 13 protofilaments assembled from α and β tubulin heterodimers. Because the α/β tubulin dimers are organized in a headto-tail fashion, the microtubules are polarized structures with a "minus" end, from which microtubules are nucleated, and a "plus" end, where polymerization of tubulin dimers occurs. The microtubule plus ends cycle between phases of growth and shrinkage, a property termed dynamic instability (1) . The net growth of microtubule polymers is determined by the rate of dimer addition and the time that the plus ends spend in the growth phase. A major recent advance has been the discovery of proteins that bind to tubulin dimers or microtubule plus ends and regulate microtubule polymerization and stability (2) . Although these proteins are under intensive investigation in nonneuronal cells, we still know little about how they regulate microtubule assembly during axon growth and regeneration. In particular, we are still missing links between well-studied axon growth-promoting and axon growthinhibiting extracellular signals and the regulation of microtubule assembly.
Two papers recently published in Cell (3, 4) , together with other recent work (5), suggest that glycogen synthase kinase 3β (GSK-3β) is a crucial player in the regulation of axon morphogenesis downstream of phosphatidylinositol 3-kinase (PI3K) signaling. First purified in 1980, GSK-3β is a serine/threonine kinase that mediates the inactivation of glycogen synthase. Surprisingly, GSK-3β has emerged as a key regulatory kinase in the nervous system with involvement in processes ranging from neural development to mood stabilization to neurodegeneration (6) .
Unlike many other kinases, GSK-3β is usually active in resting cells. Upon activation of the PI3K signaling pathway, GSK-3β is inactivated through phosphorylation of the serine-9 residue in its amino-terminal region (7). In the two new studies, Jiang et al. (3) and Yoshimura et al. (4) show that specification of rapidly elongating axonal processes versus more slowly growing dendritic processes in hippocampal neurons is regulated by GSK-3β activity. Spatially localized inactivation of GSK-3β by PI3K in a single immature neurite was necessary for future axon specification and maintenance, whereas global inactivation of GSK-3β led to the formation of multiple axons. Remarkably, inhibition of GSK-3β activity
CELL BIOLOGY

GSK-3β and Microtubule Assembly in Axons
Feng-Quan Zhou and William D. Snider
The authors are at the University of North Carolina Neuroscience Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. E-mail: wsnider@med.unc.edu with specific kinase inhibitors was even able to turn mature dendrites into axons (3). Yoshimura et al. also showed that hippocampal axon growth triggered by neurotrophin stimulation was dependent on GSK-3β inactivation. These latter findings are in line with previous work in dorsal root ganglion neurons showing that localized inactivation of GSK-3β at the growth cone is required for rapid axon elongation induced by nerve growth factor (5).
The ability of GSK-3β to control axon morphogenesis presumably relies on its ability to regulate a number of different microtubule binding proteins (MBPs). A fascinating picture is emerging in which these different MBPs may regulate specific aspects of microtubule assembly. For example, Fukata et al. (8) recently demonstrated that collapsin response mediator protein 2 (CRMP-2) binds to α/β tubulin dimers and thus regulates microtubule polymerization. The ability of CRMP-2 to bind to tubulin dimers is abolished when it is phosphorylated by GSK-3β (4). Thus, inactivation of GSK-3β results in CRMP-2 dephosphorylation, which leads to enhanced microtubule polymerization and axon growth. Indeed, hippocampal neurons induced to express a mutant version of CRMP-2 that cannot be phosphorylated by GSK-3β formed multiple axons.
Another MBP regulated by GSK-3β is adenomatous polyposis coli (APC), a tumor suppressor protein first identified as the product of the gene mutated in familial adenomatous polyposis (characterized by a predisposition to developing intestinal polyps and colon cancer) (9) . This MBP then was found to belong to a group of proteins that copolymerize with microtubules at their plus ends, termed plus end tracking proteins (+TIPS). These +TIPS promote microtubule stabilization by increasing the time that microtubules spend in the growth phase (2). Similar to CRMP-2, phosphorylation of APC by GSK-3β prevents its ability to bind to microtubules (10) . GSK-3β inactivation induced by nerve growth factor via the PI3K signaling pathway enhances APCmicrotubule interactions, which is functionally necessary for the axonal growth induced by nerve growth factor (5). Taken together, these studies indicate that inactivation of GSK-3β downstream of PI3K controls both microtubule polymerization and stabilization via the simultaneous regulation of multiple MBPs.
MAP1b is another well-known target of GSK-3β. There is evidence that phosphorylated MAP1b destabilizes microtubules and maintains them in a dynamic state (11) . The dynamic property of microtubules (which cycle between growth and shrinkage) enables them to efficiently probe the intracellular space and respond to extracellular signals. Inhibiting microtubule dynamics in neurons even without affecting microtubule polymerization retards axon growth and impairs axon guidance and branching in response to guidance cues (1) . In marked contrast to APC and CRMP-2, MAP1b is activated by GSK-3β phosphorylation. Inhibition of GSK-3β activity abolishes MAP1b phosphorylation and reduces microtubule dynamics. Interestingly, phosphorylated MAP1b is also found at the distal ends of growing axons, thus colocalizing with dephosphorylated APC and CRMP-2 (11).
How can GSK-3β be active toward some substrates and inactive toward others at the same time and in the same place? The answer may lie in how GSK-3β recognizes and phosphorylates its substrates. A special feature of GSK-3β is that it phosphorylates substrates that have been "primed" by other kinases. The kinase activity of GSK-3β toward these "primed" substrates is abolished when its amino-terminal serine-9 residue is phosphorylated by kinases downstream of PI3K. Both APC and CRMP-2 are examples of "primed" substrates (4, 10) . However, there is emerging evidence that serine-9 phosphorylation has little effect on GSK-3β activity toward substrates that do not require "priming" (7). MAP1b is thought to be one such "unprimed" substrate (11) . Thus, GSK-3β may phosphorylate MAP1b and maintain microtubule dynamics even when it is phosphorylated at serine-9. Interestingly, the different activities of GSK-3β toward primed versus unprimed substrates may be regulated by distinct signaling mediators. Accumulating evidence shows that the activity of GSK-3β toward its primed substrates, such as APC and CRMP-2, is blocked by PI3K. Studies from Gordon-Weeks's group suggest that the activity of GSK-3β toward MAP1b is increased via the activation of extracellular signal-regulated kinase (ERK) (12) .
In addition to neurotrophins, other extracellular factors that enhance axon growth or attract axons, such as Wnts and Netrin, affect GSK-3β activity. However, these signals regulate GSK-3β activity via distinct pathways. For instance, Wnt proteins that attract growing axons (13) and enhance axon branching (14) inactivate GSK-3β (independently of serine-9 phosphorylation) through their Frizzled receptors (7) . Netrin, on the other hand, acts in a similar way to neurotrophins, regulating GSK-3β activity through serine-9 phosphorylation (15) (and also regulating GSK-3β activity toward MAP1b). Moreover, GSK-3β is also an important regulator of Hedgehog signaling, yet another pathway that influences axon guidance (16) . For all of these pathways, it will be important to investigate the part played by MBPs downstream of GSK-3β in mediating the morphological response of neurons.
Factors that inhibit or repel axon growth, such as semaphorin 3A, activate GSK-3β by inhibiting serine-9 phosphorylation, thereby constituting a particularly important regulatory mechanism. Thus, the localization of serine-9 phosphorylation in the growth cones of dorsal root ganglion neurons observed in the presence of nerve growth factor is abolished by addition of nanomolar concentrations of semaphorin 3A (17) . One study suggests that semaphorins antagonize neurotrophin signaling (18) . Activation of semaphorin signaling and subsequent GSK-3β activation result in phosphorylation and inactivation of CRMP-2, which then impairs microtubule polymerization (19) . Taking all of these findings together, it seems that GSK-3β may be a critical node where multiple extracellular cues converge to regulate axon morphogenesis. Growth-promoting activities result in phosphorylation of GSK-3β at 
GSK-3β
A three-pronged assembly task for GSK-3β. GSK-3β regulates all three aspects of microtubule assembly in axons. To promote axon assembly, neurotrophins inactivate GSK-3β by phosphorylation of serine-9 via the PI3K signaling pathway. Phosphorylation of GSK-3β allows dephosphorylation of CRMP-2 and APC, which in turn promote microtubule polymerization and stabilization. Neurotrophins also enhance the activity of GSK-3β toward MAP1b (independent of serine-9 phosphorylation) via the ERK pathway. Phosphorylation of MAP1b ensures maintenance of microtubule dynamics. Coordinated regulation of microtubule polymerization, stabilization, and dynamics ensures optimal microtubule assembly in axons. Wnt proteins inactivate GSK-3β via mechanisms independent of serine-9 phosphorylation and may regulate some of the same MBPs to control axon morphogenesis. Extracellular cues that repel axon growth, such as semaphorin, may regulate GSK-3β activity in the direction opposite to that of neurotrophins, resulting in axon repulsion.
www.sciencemag.org SCIENCE VOL 308 8 APRIL 2005 P ERSPECTIVES serine-9 or inactivation via other signaling pathways. In contrast, growth-inhibitory signals act in the opposite direction to dephosphorylate the serine-9 residue.
All of these results suggest a potential strategy for promoting axonal regeneration after neural injury using pharmacological inhibitors of GSK-3β. Indeed, we have recently demonstrated that inactivation of GSK-3β is necessary for axon regeneration from mature neurons of the peripheral nervous system after nerve transection (20) . However, it must be emphasized that efficient axon extension probably requires localized inactivation of GSK-3β at the distal end of the growing axon, as well as activity of GSK-3 toward "unprimed" substrates. Although low concentrations of GSK-3β inhibitors lead to elaboration of multiple axons by hippocampal neurons, more complete global inhibition of GSK-3β almost certainly impedes axon growth (5, 14) . Thus, manipulation of GSK-3β may be a promising therapeutic strategy to promote functional recovery after injury to the central nervous system. But an important challenge remains how to achieve appropriate local regulation of GSK-3β using pharmacological inhibitors or gene therapeutic constructs.
GSK-3β may be a "master" kinase that mediates convergent signals from multiple extracellular cues affecting axon morphogenesis. It achieves this by coordinating regulation of all three aspects of microtubule assembly: polymerization, stabilization, and dynamics (see the figure) . However, regarding the functions of GSK-3β in regulating neuronal morphology, its control of microtubule assembly may only be the "tip of the iceberg." GSK-3β almost certainly regulates actin filaments, the other important component of the axonal cytoskeleton (17) . Furthermore, GSK-3β presumably regulates metabolism required for axon growth both locally in the axon and at the level of gene transcription by controlling the NFAT (nuclear factor of activated T cells) family of transcription factors and possibly other transcriptional regulators. Surprisingly, in view of its importance, the nervous system of mice that lack GSK-3β has not been extensively analyzed, and no animals lacking the related isoform, GSK-3α, have yet been reported. Developing inhibitors of GSK-3β is a major target of the pharmaceutical industry because of the potential of such drugs for treating type 2 diabetes and Alzheimer's disease. The success of lithium in treating mood disorders may reflect its ability to inhibit GSK-3β, among other effects (6) . Given the evidence that GSK-3β is important for regulating nervous system development, the use of GSK-3β inhibitors during pregnancy will need to be very carefully evaluated.
